Biologics Market

Biologics Market (2022 to 2032)

The global biologics market was valued at around US$ 335.43 Billion at the end of 2021. The market is projected to register an 8.5% CAGR and top a valuation of US$ 817.48 Billion by 2032.

Rising incidence of chronic diseases and their diagnoses, increasing government initiatives, and increased availability of advanced diagnostics are expected to uplift the biologics market growth.

Biologic drugs are produced by genetic engineering and are composed of proteins taken from human genes. Biologic medications are made up of items like blood and blood components, gene therapy, somatic cells, vaccines, allergens, tissues, and recombinant therapeutic proteins and are obtained from several natural sources, including animals, humans, or microorganisms. Disease-modifying antirheumatic medicines (DMARDs) that contain living organism components or are made from living organisms are known as biologics or biological drugs. Biologics are produced using complex methods and Advanced biotechnology techniques.

Attributes	Details
Biologics Market Value in 2021	US$ 335.4 Billion
Biologics Market Value in 2032	US$ 817.4 Billion
Biologics Market CAGR (2022 to 2032)	8.5%

What are the Major Drivers Boosting the Demand for Biologics Market?

A significant element influencing the biologics market's growth rate throughout the forecast period is the rising prevalence of chronic diseases. Oral product efficacy for Crohn's and rheumatoid arthritis attract more moderate patients to the biologics drug and new treatments. The market for biologics is being driven by factors such as big brand-name drugs losing their patent rights, an increase in the prevalence of chronic diseases and the diagnosis of those diseases, and an increase in the technological advancements in research and development by major key players of the pharmaceutical industry. Additionally, researchers are looking toward species and expression systems that have the potential to be more productive. Revenue growth is expected to be fuelled by the development of cell lines and reagents that increase the productivity of biological products.

Which Region Shows Strong Growth Potential in the Biologics Market?

The established economy of North America is anticipated to drive demand for biologics, followed by Europe and Asian regions. The overall sales of biologics in North America are anticipated to increase as the systematic drug review process and increasing technological advancement in the healthcare industry.

Furthermore, greater patient awareness, innovative strategies developed by key players, and regulatory harmonization regions are expected to experience rapid growth in the biologics control market in the European regions.

Moreover, the Middle East and Africa regions are likely to experience sustainable growth in the forecast period due to rising disease incidences in these countries.

Who are the Key Players in the Biologics Market?

Some of the market players operating in the biologics market are Novartis AG, Pfizer Inc, Dickinson & Company, Smiths Medicals, Roche Diagnostics, AstraZeneca, Bayer AG, GSK Biologicals, Samsung BioLogics, Merck & Co., Inc., Eli Lilly, and Company, Hoffmann-La Roche Ltd and AstraZeneca.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 8.5% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2012 to 2021
Forecast Period	2022 to 2032
Qualitative Units	Revenue in USD Billion, and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segment Covered	Product Application Drug Classification Mode of Purchase Distribution Channel Region
Region Covered	North America Latin America Europe East Asia South Asia Oceania Middle East & Africa
Key Countries Profiled	USA Canada Brazil Mexico Germany United Kingdom France Spain Italy China Japan South Korea Malaysia Singapore Australia New Zealand GCC Countries South Africa Israel
Key Players	Novartis AG Pfizer Inc Dickinson & Company Smith’s Medicals Roche Diagnostics AstraZeneca Bayer AG GSK Biologicals Samsung BioLogics Merck & Co., Inc. Eli Lilly and Company Hoffmann-La Roche Ltd AstraZeneca.
Customization	Available Upon Request

Key Segments Covered in the Biologics Industry Survey

By Product:

• Monoclonal Antibodies
• Recombinant Hormones/Proteins
• Vaccines
• Cellular Based Biologics
• Gene-Based Biologics
• Therapeutic Enzymes
• Others

By Application:

• Infectious Diseases
• Cancer
• Autoimmune Diseases
• Rare Diseases
• Others

By Drug Classification:

• Branded Drugs
• Generic Drugs

By Mode of Purchase:

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Frequently Asked Questions

What is the Growth Outlook for the Global Biologics Market?

The global biologics market is anticipated to register a CAGR of 8.5% during the forecast period.

Who are the Key Players in the Biologics Market?

The top players in the global biologics market are Novartis AG, Pfizer Inc, Dickinson & Company, Smiths Medicals, Roche Diagnostics, AstraZeneca, Bayer AG, GSK Biologicals, Samsung BioLogics, Merck & Co., Inc., Eli Lilly, and Company, Hoffmann-La Roche Ltd and AstraZeneca.